Tags

Type your tag names separated by a space and hit enter

COVID-19: Coronavirus Vaccine Development Updates.
Front Immunol. 2020; 11:602256.FI

Abstract

Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, Betacoronavirus, this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development.

Authors+Show Affiliations

Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.Department of Ophthalmology, Howe Laboratory, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China. Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33424848

Citation

Zhao, Jing, et al. "COVID-19: Coronavirus Vaccine Development Updates." Frontiers in Immunology, vol. 11, 2020, p. 602256.
Zhao J, Zhao S, Ou J, et al. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020;11:602256.
Zhao, J., Zhao, S., Ou, J., Zhang, J., Lan, W., Guan, W., Wu, X., Yan, Y., Zhao, W., Wu, J., Chodosh, J., & Zhang, Q. (2020). COVID-19: Coronavirus Vaccine Development Updates. Frontiers in Immunology, 11, 602256. https://doi.org/10.3389/fimmu.2020.602256
Zhao J, et al. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020;11:602256. PubMed PMID: 33424848.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19: Coronavirus Vaccine Development Updates. AU - Zhao,Jing, AU - Zhao,Shan, AU - Ou,Junxian, AU - Zhang,Jing, AU - Lan,Wendong, AU - Guan,Wenyi, AU - Wu,Xiaowei, AU - Yan,Yuqian, AU - Zhao,Wei, AU - Wu,Jianguo, AU - Chodosh,James, AU - Zhang,Qiwei, Y1 - 2020/12/23/ PY - 2020/09/07/received PY - 2020/11/26/accepted PY - 2021/1/11/entrez PY - 2021/1/12/pubmed PY - 2021/1/16/medline KW - Coronavirus Disease 2019 (COVID-19) KW - Middle-East Respiratory Syndrome KW - Severe Acute Respiratory Syndrome KW - Severe Acute Respiratory Syndrome Coronavirus 2 KW - vaccine SP - 602256 EP - 602256 JF - Frontiers in immunology JO - Front Immunol VL - 11 N2 - Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, Betacoronavirus, this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/33424848/COVID_19:_Coronavirus_Vaccine_Development_Updates_ L2 - https://doi.org/10.3389/fimmu.2020.602256 DB - PRIME DP - Unbound Medicine ER -